M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice

Neuropsychopharmacology

Volumn 19, Issue 1, 1998, Pages 74-85

  Wang, Rex Y ^a   Liang, Xiaofu ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

5 HT(2A) receptors; Antipsychotic drugs; Medial prefrontal cortex; NMDA receptors; Phencyclidine; Pyramidal cells

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LIDOCAINE ETHOBROMIDE; M 100009; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; RACLOPRIDE; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PYRAMIDAL NERVE CELL; RAT; RECEPTOR BLOCKING;

EID: 0031800006     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00003-7     Document Type: Article

References (91)

1. Alessandri B, Battig K, Welzl H Effects of ketamine on tunnel maze and water maze performance in the rat. Behav Neural Biol. 52:1989;194-212.
2. Allen RM, Young SJ Phencyclidine-induced psychosis. Am J Psychiatry. 135:1978;1081-1084.
3. Arvanov VL, Wang RY NMDA-evoked response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res. 768:1997;361-364.
4. 2A receptor antagonist and a potential antipsychotic drug, facilitates NMDA-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology. 3:1998;197-209.
5. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY Clozapine and haloperidol modulate NMDA and non-NMDA receptor mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther. 283:1997;226-234.
6. 2 receptors in the medial prefrontal cortex. Microiontophoretic studies Brain Res. 506:1990;346-348.
7. Bakshi VP, Swerdlow NR, Geyer MA Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 271:1994;787-794.
8. Berretta N, Jones RSG Tonic facilitation of glutamate release by presynaptic N-methyl-D-aspartate autoreceptors in the entorhinal cortex. Neuroscience. 75:1996;339-344.
9. Bleeker ED, Versleger W Ritanserin in the treatment of negative symptoms in chronic schizophrenic patients. Abstracts of the 17th Congress of CINP, Kyoto, Japan:1990;221. Vol. II, p.
10. 2 receptors and serotonergic axons in rat neocortex. Brain Res. 453:1988;315-328.
11. Boyce S, Rupniak NMJ, Stevenson MJ, Cook G, Iversen SD Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primates. Behav Brain Res. 42:1991;115-121.
12. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr. Effect of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 151:1994;20-26.
13. Bryk A, Raudenbush S Hierarchical Linear Models. Applications and Data Analysis Methods:1992;Sage Publications, Newbury Park, CA.
14. Carlsson M, Carlsson A Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Pharmacol Sci. 13:1990;272-276.
15. Cassens G, Inglis A, Appelbaum P, Gutheil T Neuroleptics. Effects on neuropsychological function in chronic schizophrenic patients Schizophr Bull. 16:1990;477-499.
16. Cauli B, Audinat E, Lambolez B, Angulo MC, Ropert N, Tsuzuki K, Hestrin S, Rossier J Molecular and physiological diversity of cortical nonpyramidal cells. J Neurosci. 17:1997;3894-3906.
17. Connick JH, Stone TW Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol. 93:1988;868-876.
18. Connors BW, Gutnick MJ Intrinsic firing patterns of diverse neocortical neurons. Trends Pharmacol Sci. 13:1990;99-104.
19. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
20. Danysz W, Wroblewski JT, Costa E Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacol. 27:1988;653-656.
21. Deutsch SI, Mastrpaolo J, Schwartz BL, Rosse RB, Morihisa JM A "glutamatergic hypothesis" of schizophrenia. rationale for pharmacology with glycine Clin Neuropharmacol. 12:1989;1-13.
22. Diggle PJ An approach to the analysis of repeated measurements. Biometrics. 44:1988;959-971.
23. Donaldson JO, Baselt RC CSF phencyclidine. Am J Psychiatry. 136:1979;1341-1342.
24. 1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry. 163:1993;451-455.
25. Dure LSIV, Young AB The distribution of glutamate receptor subtypes in mammalian central nervous system using quantitative in vitro autoradiography. Stone TW CNS Neurotransmitters and Neuromodulators. Glutamate:1995;83-94 C Press, New York, CR.
26. Farber N, Foster J, Duhan NL, Olney JW Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr Res. 21:1996;33-37.
27. Finkel AS, Redman SJ Optimal voltage clamping with single microelectrodes. Smith TG, Lecar A, Redman SJ, Gage PW Voltage and Patch Clamping with Microelectrodes. 1985;95-120 Williams & Wilkins, Baltimore.
28. Fujii DEM, Ahmed I, Jokumsen M, Compton JM The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry. 9:1997;240-245.
29. Gelders Y, VandenBussche G, Reyntjens A, Janssen P Serotonin-S2 receptor blockers in the treatment of chronic schizophrenia. Clin Neuropharmacol. 9:1986;325-327.
30. Gleason SD, Shannon HE Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine, and serotonin receptor subtype selective antagonists in mice. Psychopharmacology. 129:1997;79-84.
31. Goldberg TE, Weinberger DR The effect of clozapine on neurocognition. An overview J Clin Psychiatry. 55(suppl B):1994;88-90.
32. Goldman-Rakic PS, Selemon LD Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bull. 23:1997;437-458.
33. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry. 34:1993;702-712.
34. Haller E, Binder RL Clozapine and seizures. Am J Psychiatry. 147:1990;1069-1071.
35. Halliwell JV, Adams PR Voltage clamp analysis of muscarinic excitation in hippocampal neurons. Brain Res. 250:1982;71-92.
36. Hertzman M, Reba RC, Kotlyarove EV Single photon emission computerized tomography in phencyclidine and related drug abuse. Am J Psychiatry. 147:1990;255-256.
37. Honey CR, Miljkovic Z, McDonald JF Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci Lett. 61:1985;135-139.
38. Ingvar DH, Franzen G Distribution of cerebral activity in chronic schizophrenia. Lancet. 2:1974;1484-1486.
39. Javitt DC, Zukin SR Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
40. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH Subchronic phencyclidine) administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology. 17:1997;92-99.
41. Jentsch JD, Redmond DB Jr., Elsworth JD, Taylor JR, Youngren D, Roth RH Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 277:1997;953-955.
42. Kawaguchi Y, Kubota Y Physiological and morphological identification of somatostatin or vasoactive intestinal polypeptide-containing cells among GABAergic cell types in rat frontal cortex. J Neurosci. 16:1996;2701-2715.
43. Kay SR, Sevy S Pyramidal model of schizophrenia. Schizophr Bull. 16:1990;537-545.
44. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther. 277:1996;968-981.
45. Keith VA, Mansbach RS, Geyer MA Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry. 30:1991;557-566.
46. Kim JS, Kornhuber J, Schmid-Burgk W, Holzmuller B Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 20:1980;379-382.
47. Kristensen JD, Svensson B, Gordh T The NMDA receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain. 51:1992;249-253.
48. Krystal JH, Karper LP, Seibyl IP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr., Charney DS Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiat. 51:1994;199-214.
49. Lahti AC, Koffel B, LaPorte D, Tamminga CA Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 13:1995;9-19.
50. Lee MA, Thompson PA, Meltzer HY Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 55:1994;9. suppl B) 82-87.
51. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP Antiglutamatergic effects of clozapine. Neurosci Lett. 163:1993;155-158.
52. Littell RC, Milliken GA, Stroup WW, Wolfinger RD (1996): SAS System for Mixed Models. SAS Institute Inc., Cary, NC.
53. Lynch DR, Gallagher MJ Inhibition of N-methyl-D-aspartate receptors by haloperidol. Developmental and pharmacological characterization in native and recombinant receptors J Pharm Exp Ther. 279:1996;154-161.
54. MacDonald JF, Miljkovic Z, Pennefather P Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Physiol. 58:1987;251-266.
55. Madison DV, Lancaster B, Nicoll RA Voltage clamp analysis of cholinergic action in the hippocampus. J Neurosci. 7:1987;733-741.
56. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A NMDA receptor function and human cognition. The effects of ketamine in healthy volunteers Neuropsychopharmacology. 14:1996;301-307.
57. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, Breier A Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 17:1997;141-150.
58. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A Clozapine blunts N-methy-D-aspartate antagonist-induced psychosis. A study with ketamine Biol Psychiat. 42:1997;664-668.
59. 2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J Neural Transm. 104:1997;561-564.
60. 2 presynaptic receptors mediate inhibition of glutamate release from cerebellar mossy fiber terminals. Eur J Pharmacol. 202:1991;185-190.
61. 2A receptors. Eur J Pharmacol. 280:1995;R9-R11.
62. McCormick DA, Connors BW, Lighthall JW, Prince DA Comparative electrophysiology of pyramidal and sparsely spiny neurons of the neocortex. J Neurophysiol. 54:1985;782-806.
63. Meltzer HY Clozapine. Is another view valid? Am J Psychiatry. 152:1995;821-825.
64. i values. J Pharmacol Exp Ther. 251:1989;238-246.
65. Meltzer HY, Thompson PA, Lee MA, Ranjan R Neuropsychologic deficits in schizophrenia. Relation to social function and effect of antipsychotic drug treatment Neuropsychopharmacology. 14(3S):1996;27S-33S.
66. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res. 524:1990;139-143.
67. Moghaddam B Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 18:1994;859-870.
68. Montague PR, Gancayco CD, Winn MJ, Marchase RB, Friedlander MJ Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science. 263:1994;973-977.
69. 2A receptor antagonist, in rats. Br J Pharmacol. 121:1997;515-525.
70. Olney JW, Farber NB Glutamate receptor disfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
71. Pearlson GD Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J. 148:1981;25-33.
72. Rosse RB, Mastropaolo J, Sussman DM, Koetzner L, Morn CB, Deutsch SI Computerized measurement of MK-801-elicited popping and hyperactivity in mice. Clin Neurophamacol. 18:1995;448-457.
73. Schweitzer P, Madamba S, Champagnat J, Siggins GR Somatostatin inhibition of hippocampal CA1 pyramidal neurons. Mediation by arachidonic acid and its metabolites J Neurosci. 13:1993;2033-2049.
74. 2A antagonist MDL 100907 as a putative atypical antipsychotic. Behavioral, electrophysiological, and neurochemical studies J Pharmacol Exp Ther. 266:1993;1-8.
75. Swerdlow NR, Bakshi V, Geyer MA Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther. 279:1996;1290-1299.
76. Tarazi FI, Floriji J, Creese I Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology. 128:1996;371-379.
77. Verma A, Moghaddam B NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats. Modulation by dopamine J Neurosci. 16:1996;373-379.
78. Wachtel H, Turski L Glutamate. A new target in schizophrenia Trends Pharmacol Sci. 11:1990;219-220.
79. Walberg CB, McCarron MM, Schulze BW Quantitation of phencyclidine in serum by enzyme immunoassay. Results in 405 patients J Anal Toxicol. 7:1983;106-110.
80. 2A receptor antagonist and a potential atypical antipsychotic drug, facilitates induction of long-term potentiation in area CA1 of the rat hippocampal slice. Brain Res. 779:1998;309-313.
81. Weinberger DR, Berman KF Prefrontal function in schizophrenia. Confounds and controversies Phil Trans R Soc Lond B. 351:1996;1495-1503.
82. Weinberger DR, Berman KF, Zec RF Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry. 43:1986;114-125.
83. Weinberger DR, Berman KF, Illowsky BP Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanism. Arch Gen Psychiatry. 45:1988;609-615.
84. Weinberger DR, Lipska BK Cortical maldevelopment, antipsychotic drugs, and schizophrenia. A search for common ground Schizophrenia Res. 16:1995;87-110.
85. White IM, Flory GS, Hooper KC, Speciale J, Banks DA, Rebec GV Phencyclidine-induced increases in striatal neuron firing in behaving rats. Reversal by haloperidol and clozapine J Neural Transmission. 102:1995;99-112.
86. Wiesel FA, Nordstrom AL, Farde L, Eriksson B An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology. 114:1994;31-38.
87. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
88. Witkin JM Role of NMDA receptors in behavior and behavioral effects of drugs. Stone TW CNS Neurotransmitters and Neuromodulators. Glutamate:1995;323-350 C Press, New York, CR.
89. Wu JC, Buchsbaum MS, Bunney WE Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia. Jpn J Psychopharmacol. 11:1991;47-48.
90. Yang CR, Seamans JK, Gorelova N Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J Neurosci. 16:1996;1904-1921.
91. Zar JH Biostatistical Analysis. 1996;Prentice Hall, Upper Saddle River, NJ.